Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599198 | 0.89 | KMT2A (0.44) | PTGS2HSD17B10LMNAMAPTALDH1A1 | |
| Benzene SCHEMBL16599421 | 0.87 | KDM4E (0.51) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL29454034 | 0.86 | PTGS2 (0.64) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL4138781 | 0.86 | PTGS2 (0.64) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL6400514 | 0.85 | KDM4E (0.52) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Ncx-4016 SCHEMBL29813476 | 0.85 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL17986190 | 0.85 | PTGS2 (0.46) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Ncx-4016 SCHEMBL29546681 | 0.85 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Ncx-4016 SCHEMBL19524 | 0.85 | PTGS2 (0.57) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL16599365 | 0.83 | PTGS2 (0.48) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | claimed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | PTGS2 91/4885HSD17B10 647/4885KDM4E 3253/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | PTGS2 64/4885HSD17B10 606/4885KDM4E 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.